Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population
Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population
复制标题
DOI：
10.1002/ijc.20477
复制
发表时间：
2004-12-10
影响因子：
6.4
通讯作者：
Kato, T
中科院分区：
文献类型：
--
作者：
Narita, S;Tsuchiya, N;Kato, T
高脂肪摄入与前列腺癌的发生有关，脂蛋白脂酶（LPL）基因多态性在血浆脂蛋白代谢中起重要作用。我们在此分析了日本人群中LPL基因多态性与前列腺癌风险的相关性。采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法检测了273例前列腺癌患者、205例良性前列腺增生（BPH）患者和230名男性对照者LPL基因的Ser 447 stop、HindIII和PvuII单核苷酸多态性（SNPs）。Ser 447 stop多态性的CG + GG基因型的男性与CC基因型的男性相比，患前列腺癌的风险增加[年龄校正比值比（aOR）= 1.625; 95%CI = 1.068-2.471; p = 0.023]。此外，CG + GG基因型相关的风险增加在高级别癌症患者中更为明显（aOR = 2.843; 95% CI = 1.252-6.458; p = 0.039）或转移性疾病（aOR = 2.300; 95%CI = 1.042-5.074; p = 0.013），而在低至中度癌症或非转移性疾病患者中，风险并不显著。在HindIII和PvuII多态性中，前列腺癌患者与对照组之间没有显著差异，并且对于肿瘤分级和分期没有显著结果。3个多态性均未显示与BPH的风险相关。我们的研究结果表明，LPL Ser 447 stop多态性是一种常见的遗传修饰的前列腺癌的发展，特别是高级别和/或高阶段，在日本人口。(C)2004 Wiley-Liss，Inc.
A high fat intake has been associated with prostate cancer risk, and gene polymorphisms of lipoprotein lipase (LPL) play an important role in plasma lipoprotein metabolism. We herein analyzed the association of LPL gene polymorphisms with the risk of prostate cancer in a Japanese population. Three single nucleotide polymorphisms (SNPs) of LPL designated as Ser447stop, HindIII and PvuII were genotyped by the polymerase chain reaction-restriction fragment length polymorphism method in 273 prostate cancer patients, 205 benign prostatic hyperplasia (BPH) patients and 230 male controls. The men with the CG + GG genotypes of the Ser447stop polymorphism had an increased risk of prostate cancer compared to those with the CC genotype [age-adjusted odds ratio (aOR) = 1.625; 95% CI = 1.068-2.471; p = 0.023]. Furthermore, the increased risk associated with the CG + GG genotypes was more strongly observed in patients with high-grade cancers (aOR = 2.843; 95% CI = 1.252-6.458; p = 0.039) or metastatic diseases (aOR = 2.300; 95% CI = 1.042-5.074; p = 0.013), whereas the risk was not significant in those with low- to intermediate-grade cancers or nonmetastatic diseases. In the HindIII and PvuII polymorphisms, there was no significant difference between the prostate cancer patients and the controls, and no significant results as for tumor grade and stage. None of the 3 polymorphisms showed any association with the risk of BPH. Our results suggest that the LPL Ser447stop polymorphism is a common genetic modifier for the development of prostate cancer, particularly that of high-grade and/or high-stage, in a Japanese population. (C) 2004 Wiley-Liss, Inc.